The EFTISARC-NEO trial, with a data cut-off of 20 October 2024, also showed 71.4% of patients achieved a pathologic response ...

Adaptimmune Therapeutics’ lete-cel data achieves primary endpoint in pivotal phase 2 IGNYTE-ESO trial: Philadelphia Friday, November 15, 2024, 13:00 Hrs [IST] Adaptimmune Therap ...

Immutep (IMMP) announces the presentation of new data from EFTISARC-NEO, a Phase II investigator-initiated trial of eftilagimod alpha in ...

Synovial sarcoma and MRCLS are rare and often aggressive cancers with limited treatment options. Synovial sarcoma is a soft ...

A cell therapy developer with operations at the Philadelphia Navy Yard plans reduce its headcount by 33% next year as it ...

Company remains on track for first subject treated in pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) in the first quarter of 2025 ...

Immutep also reported on new data from a Phase II trial of efti in combination with radiotherapy plus pembrolizumab for ...

Shares of Immutep (NASDAQ:IMMP) climbed 11% Thursday after the Australian company reported positive data from two clinical trials of its drug candidate eftilagimod alpha, or efti. Immutep (IMMP) said ...

Leading the charge was Xero (ASX:XRO), which soared 6 per cent after the accounting software company revealed a stellar ...

Secondly, Immutep presented positive phase II data from the EFTISARC-NEO trial in soft tissue sarcoma. The trial showed that ...

If I only have around three years left to live, what's the point in A-levels?" According to bone and soft tissue cancer ...

Media Release Mature data in patients with a minimum follow-up of 22 months (N=21) shows excellent results, well above historical controls and exceeding expectations: Median Overall Survival is 32.9 ...